Endometriosis Treatment Market Size, Share Report, Analysis, Trends, Growth, 2030

Industry Prospective:

The global endometriosis treatment market size was worth around USD 1.3 billion in 2022 and is predicted to grow to around USD 3.21 billion by 2030 with a compound annual growth rate (CAGR) of roughly 13.51% between 2023 and 2030. The report analyzes the global endometriosis treatment market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the endometriosis treatment industry.

Request Free Sample

Endometriosis Treatment Market: Overview

Endometriosis is a medical condition that impacts the female segment of the population. Endometrial tissue typically acts as the lining for the uterus which is a female reproductive organ. In this condition, the tissue starts to grow outside of it leading to infertility or chronic pain. The industry refers to the various stakeholders that deal with condition diagnosis and treatment. It includes medicines and therapies involved to manage the symptoms of the condition. There are various types of drugs that are a part of the distribution system in the fraternity and include hormonal therapies like oral contraceptives and non-steroidal anti-inflammatory drugs (NSAIDs) along with certain surgical processes. These treatments are intended to provide pain relief or prevent the progression of the disease. The industry is registering higher growth due to multiple factors but is expected to witness challenges along the way.

Key Insights: 

• As per the analysis shared by our research analyst, the global endometriosis treatment market is estimated to grow annually at a CAGR of around 13.51% over the forecast period (2023-2030)
• In terms of revenue, the global endometriosis treatment market size was valued at around USD 1.3 billion in 2022 and is projected to reach USD 3.21 billion, by 2030.
• The market is projected to grow at a significant rate due to the growing prevalence of the disease
• Based on route of administration segmentation, oral was predicted to show maximum market share in the year 2022
• Based on drug class segmentation, NSAIDs was the leading class in 2022
• On the basis of region, North America was the leading revenue generator in 2022

Request Free Sample

Endometriosis Treatment Market: Growth Drivers

Growing prevalence of the medical condition to drive market demand

The global endometriosis treatment market is projected to grow owing to the rising prevalence of the condition. The disease is extremely common and is known to impact 10% of the female population that has reached reproductive age. The condition is further impacted due to the non-availability of accurate diagnostic tools. Currently, the medical community does not have the answer to the exact cause of the condition making medicine development a tedious and completed task.

This has led to the piling of cases from multiple years in the past due to factors like lack of awareness, absence of sufficient treatment and diagnostic facilities, and general ignorance toward the condition. However, various government and non-government healthcare agencies have initiated mass campaigns to educate people about the condition and possible medication or therapies available at their disposal, leading to more patients coming out for seeking treatment. Changing the perception of the menstrual cycle and the medical problems associated with it has played a crucial role in the industry's growth in the last few years.

Endometriosis Treatment Market: Restraints

Absence of a cure to restrict the market growth

There are certain medical conditions that do not have any cure even in the advanced medical world. Endometriosis is one such condition since there is no permanent treatment for the condition. It can only be treated in terms of symptom management and delaying or stopping the progression of the disease if diagnosed at the right time. This acts as a severe drawback for the global endometriosis treatment market since women who do not have access to accurate information on the management of this condition, could continue to suffer from it or adopt local measures to curb the pain.

Endometriosis Treatment Market: Opportunities

Growing investment toward higher research to provide further opportunities

One of the key segments the endometriosis treatment industry size may improve is the growing investment toward higher research in the field of finding a cure for endometriosis. Some of these activities include a better understanding and application of hormonal therapies under which the medical professional aims at reducing the level of estrogen in the body. Currently, there is intensive research being conducted around aromatase inhibitors, selective progesterone receptor modulators, and gonadotropin-releasing hormone agonists and antagonists.

Endometriosis Treatment Market: Challenges

High cost associated with the treatment to challenge market growth

Endometriosis treatments are expensive. These procedures are carried out over a period of time and are unlike other treatment processes that require one time visit to the doctor. Furthermore, the outcome of the medical process varies from one patient to another and hence the endometriosis treatment industry players are unable to produce a standard medicine that works for all. In addition to this, hormonal therapies associated with the treatment can have severe side effects on the patients like headache, bone loss, hot flashes, and vaginal dryness. All of these factors work against global industry growth.

Endometriosis Treatment Market: Segmentation

The global endometriosis treatment market is segmented based on drug class, treatment type, route of administration, and region.

Based on drug class, the global market segments are oral contraceptives, NSAIDs, gonadotropin releasing hormones, and others. The industry witnessed the highest growth in the NSAIDs segment which dominated almost 19.51% of the segmental share. These medications are a sub-segment of the therapeutic drug class and they assist in decreasing fever & inflammation, and preventing any type of blood clots. The medicinal plan is highly effective in relieving any intensity of pain that is caused by endometriosis and it performs its role by releasing prostaglandins.

Based on treatment type, the endometriosis treatment industry is segmented into hormone therapy and pain medication.

By route of administration, the global market divisions are injectable, oral, and others. The highest growth was observed in the oral segment, which held more than 19.8% of the share. It is also expected to grow at the fastest CAGR during the forecast period. The high demand for the product is driven by the ease of consumption offered by these medicines. Oral contraceptives are the most prescribed medicines followed by injectables. The other segments include topical creams which may grow at a higher CAGR in the coming years due to ongoing research & development activities along with product innovation and rapid approvals.

Recent Developments:

• In March 2023, the research community at the University of Edinburgh announced that they are hopeful about the potential of the new treatment plan developed for treating endometriosis. The researchers will begin clinical trials soon which will involve around 100 women from London and Edinburgh. The new treatment method makes use of non-hormonal drugs and makes use of dichloroacetate
• In August 2022, the US Food and Drugs Administration (FDA) approved the use of MYFEMBREE®, developed by Pfizer and Myovant Sciences. The medicine can be used as a once-daily treatment to manage moderate to severe pain caused by the condition. The phase 3 SPIRIT program data showed positive results in reducing the associated pain
• In November 2022, The National Institute of Health and Care Excellence (NICE) announced that it will update its guidelines surrounding the diagnosis of Endometriosis. The existing guidelines also include subjects like surgical management when fertility is important and general-case surgical management

Endometriosis Treatment Market Report Scope:

Endometriosis Treatment Market: Regional Analysis

North America to generate the highest revenue during the forecast period

The global endometriosis treatment market is projected to register the highest growth in North America. In 2022, the region dominated over 48.5% of the global market share. The growth may be driven due to the high prevalence rate of the condition along with wide-scale awareness about the various treatment plans and therapies available in the medical sector for treating the condition. Furthermore, the government of the US and Canada have undertaken multiple initiatives to promote understanding and awareness rate surrounding the condition.

In addition to this, the US is registering a high rate of FDA approvals for various new medicines and therapies which assists in improving the availability of the medication. Growth in Europe is anticipated to be led by growing demand for effective treatment of the condition along with rising research and development activities in the regional industry. The growth rate in Asia-Pacific is expected to be close to 18% during the forecast period.

Endometriosis Treatment Market: Competitive Space

The global endometriosis treatment market is led by players like:

• Bayer AG
• AbbVie Inc.
• Johnson & Johnson
• AstraZeneca plc
• Pfizer Inc.
• Roche Holding AG
• Gedeon Richter Plc
• Myovant Sciences Ltd.
• Neurocrine Biosciences Inc.
• Astellas Pharma Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Co. Ltd.
• Kissei Pharmaceutical Co. Ltd.
• Eli Lilly and Company
• Repros Therapeutics Inc.
• Ferring Pharmaceuticals Inc.
• Anika Therapeutics Inc.
• Merck & Co. Inc.
• Meditrina Pharmaceuticals Inc.

The global endometriosis treatment market is segmented as follows:

By Drug Class

• Oral Contraceptive
• NSAIDs
• Gonadotropin Releasing Hormones
• Others

By Treatment Type

• Hormone Therapy
• Pain Medication

By Route of Administration

• Injectable
• Oral
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa